Your browser doesn't support javascript.
loading
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Martínez-García, María; Servitja Tormo, Sonia; Vilariño Quintela, Noelia; Arance Fernández, Ana; Berrocal Jaime, Alfonso; Cantos Sánchez de Ibargüen, Blanca; Del Barco Berrón, Sonia; Cantos Sánchez de Ibargüen, Blanca; García Campelo, Rosario; Gironés Sarrió, Regina; Sepúlveda-Sánchez, Juan Manuel.
Affiliation
  • Martínez-García, María; Hospital del Mar. Barcelona. Spain
  • Servitja Tormo, Sonia; Hospital del Mar. Barcelona. Spain
  • Vilariño Quintela, Noelia; Institut Català d’Oncologia L’Hospitalet. Barcelona. Spain
  • Arance Fernández, Ana; Hospital Clínic. Barcelona. Spain
  • Berrocal Jaime, Alfonso; Consorcio Hospital General Universitario de Valencia. Valencia. Spain
  • Cantos Sánchez de Ibargüen, Blanca; Hospital Universitario Puerta de Hierro Majadahonda. Madrid. Spain
  • Del Barco Berrón, Sonia; Hospital Universitari Dr. Josep Trueta. Girona. Spain
  • Cantos Sánchez de Ibargüen, Blanca; Hospital Universitario Puerta de Hierro Majadahonda. Madrid. Spain
  • García Campelo, Rosario; Complexo Hospitalario Universitario A Coruña (CHUAC). A Coruña. Spain
  • Gironés Sarrió, Regina; Hospital Universitari i Politècnic la Fe. Valencia. Spain
  • Sepúlveda-Sánchez, Juan Manuel; Hospital Universitario. Madrid. Spain
Clin. transl. oncol. (Print) ; 24(4): 703-711, abril 2022. ilus
Article in English | IBECS | ID: ibc-203774
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.
Subject(s)


Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Brain Neoplasms / Central Nervous System / Central Nervous System Neoplasms / Cerebrum / Melanoma Language: English Journal: Clin. transl. oncol. (Print) Year: 2022 Document type: Article Institution/Affiliation country: Complexo Hospitalario Universitario A Coruña (CHUAC)/Spain / Consorcio Hospital General Universitario de Valencia/Spain / Hospital Clínic/Spain / Hospital Universitari Dr. Josep Trueta/Spain / Hospital Universitari i Politècnic la Fe/Spain / Hospital Universitario Puerta de Hierro Majadahonda/Spain / Hospital Universitario/Spain / Hospital del Mar/Spain / Institut Català d’Oncologia L’Hospitalet/Spain

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Brain Neoplasms / Central Nervous System / Central Nervous System Neoplasms / Cerebrum / Melanoma Language: English Journal: Clin. transl. oncol. (Print) Year: 2022 Document type: Article Institution/Affiliation country: Complexo Hospitalario Universitario A Coruña (CHUAC)/Spain / Consorcio Hospital General Universitario de Valencia/Spain / Hospital Clínic/Spain / Hospital Universitari Dr. Josep Trueta/Spain / Hospital Universitari i Politècnic la Fe/Spain / Hospital Universitario Puerta de Hierro Majadahonda/Spain / Hospital Universitario/Spain / Hospital del Mar/Spain / Institut Català d’Oncologia L’Hospitalet/Spain
...